P95 BV and LatinaBA Collaborate for Vaccine Research
P95 BV, a prominent Contact Research Organization (CRO) known for its advanced vaccine development capabilities, is proud to announce a strategic partnership with LatinaBA. Together, these two organizations aim to significantly elevate vaccine and infectious disease research across the region.
Combining Strengths for Greater Impact
This strategic alliance will effectively leverage the strengths and resources of both P95 and LatinaBA. Their collaboration emphasizes the importance of enhancing clinical and epidemiological trials, broadening the reach of services provided in clinical research across Latin America.
Leadership Insights on the Partnership
Thomas Verstraeten, the CEO of P95, expressed enthusiasm about the partnership, stating, "We are thrilled to establish a partnership that extends our close collaboration. LatinaBA has a profound understanding of the research needs across Latin America. Together with our expertise, we will better serve the interests of vaccine manufacturers and various stakeholders throughout Latin America and beyond."
Mariano Zarzecki, CEO of LatinaBA, echoed this sentiment by saying, "We are pleased to partner with P95 and kickstart our collaboration to significantly enhance vaccine research. This partnership combines our mutual strengths and opens up new opportunities for our clients, ultimately enriching treatment options available for patients in the region."
About P95 BV
P95 BV specializes in delivering all-encompassing solutions in clinical trials, with a focus on infectious diseases and global health. The organization takes pride in offering customized services that span all phases of clinical research. With a global reach and specific expertise in challenging environments such as Low- and Middle-Income Countries, P95 ensures impactful outcomes in the medical research landscape.
About LatinaBA
Established for over 15 years, LatinaBA is a leading Regional CRO that has spearheaded numerous successful clinical trials across Latin America. Their comprehensive expertise in conducting various phases of clinical trials, ranging from Medical Devices to its extensive observational studies, sets LatinaBA apart in the region. The company is dedicated to facilitating the advancement of clinical trial oversight and real-world evidence studies to enhance patient care.
Frequently Asked Questions
What is the purpose of the partnership between P95 and LatinaBA?
The partnership aims to enhance vaccine and infectious disease research in Latin America by leveraging the resources and expertise of both organizations.
How long has LatinaBA been operating?
LatinaBA has been operating as a Regional CRO for over 15 years, showcasing extensive experience in conducting clinical trials.
What services does P95 BV offer?
P95 BV provides full-service solutions related to clinical trials, epidemiology, and real-world evidence, focusing primarily on infectious diseases and global health.
Who are the key leaders of the partnering organizations?
The key leaders are Thomas Verstraeten, CEO of P95, and Mariano Zarzecki, CEO of LatinaBA, both of whom are committed to advancing vaccine research.
What types of clinical trials does LatinaBA specialize in?
LatinaBA specializes in various clinical trial phases, including those involving Medical Devices, Real-World Evidence studies, and Clinical Trial Oversight.
